Genomic Variations in CSF of Lung Cancer Patients with Brain and Meningeal Metastases

Overview

This study compared cerebrospinal fluid (CSF) genomic profiles between lung adenocarcinoma patients with combined brain parenchymal and meningeal metastases (BM&MM) and those with isolated meningeal metastases (MM). Significant molecular differences were identified, highlighting distinct mutation patterns and potential biomarkers associated with different metastatic patterns.

Background

Lung adenocarcinoma (LUAD) is the predominant subtype of non-small cell lung cancer and a leading cause of cancer mortality. Brain metastases, including brain parenchymal metastasis (BM) and meningeal metastasis (MM), are common and carry poor prognoses, with MM associated with shorter survival. Due to the blood–brain barrier, circulating tumor DNA in plasma poorly reflects intracranial lesions, making CSF a valuable liquid biopsy source for genomic profiling. Understanding molecular differences between BM and MM is critical for developing targeted therapies and improving outcomes.

Data Highlights

Key Findings

• Patients with combined BM and MM exhibited distinct CSF genomic profiles compared to those with MM only, suggesting different metastatic mechanisms.
• EGFR mutations, particularly in exons 18–21, were prevalent and are key drivers in LUAD progression and metastasis.
• Copy number variations (CNVs) were identified as potential biomarkers for metastatic pattern differentiation and prognosis.
• CSF liquid biopsy provided a more accurate reflection of intracranial tumor mutations than plasma due to the blood–brain barrier limitations.
• Differences in tumor immune microenvironment and metabolic constraints between BM and MM may influence mutation profiles and treatment responses.

Clinical Implications

CSF genomic profiling can guide personalized treatment strategies for LUAD patients with brain metastases by revealing mutation patterns specific to metastatic sites. Recognizing distinct molecular features between BM and MM may improve targeted therapy selection and help overcome drug resistance. Incorporating CSF analysis into clinical practice could enhance monitoring of intracranial disease and optimize therapeutic outcomes.

Conclusion

This study underscores the importance of CSF genomic analysis in differentiating metastatic patterns in lung adenocarcinoma brain metastases. Identifying unique molecular alterations in combined BM and MM versus isolated MM provides insights for tailored therapeutic approaches and improved patient management.

References

1. Global Cancer Statistics 2020 -- Lung Cancer Incidence and Mortality
2. Histological Subtypes of NSCLC -- Lung Adenocarcinoma Prevalence
3. Brain Metastases in Lung Cancer -- Survival and Prognosis
4. Molecular Differences in Brain Metastases -- MYC, YAP1, MMP13 Amplification
5. EGFR Mutations in LUAD -- Role in Tumor Progression and Therapy
6. CSF as Liquid Biopsy -- Reflecting Intracranial Lesion Genomics